Licensing
10 stories covering licensing — fund closes, LP allocations, regulatory filings, deal flow, and fundraising signals from PipelineRoad's editorial team.
Transgene and NEC Bio Sign License for TG4050 Development in Head and Neck Cancers
Transgene and NEC Bio announced a license agreement on April 2, 2026, for advancing TG4050, a personalized vaccine for HPV-negative head and neck cancers, including financial payments to NEC.
Transgene and NEC Bio Sign License for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for HPV-negative head and neck cancer treatment, including financial payments.
InterDigital Announces License Agreement with Buffalo Americas and New DTV Deals
InterDigital signs a patent license agreement with Buffalo Americas for Wi-Fi standards and new agreements with a global TV manufacturer, as reported in a GlobeNewswire release.
InterDigital Signs Patent License with Buffalo Americas and New TV Agreements
InterDigital announced a patent license agreement with Buffalo Americas for Wi-Fi technologies and new deals with a global TV manufacturer, as per a recent press release.
BriaCell and BriaPro Close Asset Purchase for Soluble CD80 License
BriaCell Therapeutics Corp. and BriaPro Therapeutics Corp. completed an asset purchase transaction for the exclusive Soluble CD80 license, as announced on March 31, 2026.
20/20 BioLabs Announces Exclusive U.S. License with ROKIT Healthcare
20/20 BioLabs has entered an exclusive U.S. license agreement with ROKIT Healthcare to integrate CKD prediction technology into its Longevity Test Program, as per a recent announcement.
20/20 BioLabs Secures Exclusive U.S. License with ROKIT Healthcare for CKD Technology
20/20 BioLabs announces a licensing agreement with ROKIT Healthcare to integrate CKD prediction into its longevity platform, as per GlobeNewswire PE.
Yatiri Bio Secures Exclusive Option for Denfivontinib Licensing from Oscotec
Yatiri Bio announced an exclusive global option to license denfivontinib from Oscotec for AML treatment, utilizing its AI-driven platform.
VVMF Enters Licensing Agreement with OXB for Viral Vector Platforms
Australia's Viral Vector Manufacturing Facility signs a licensing deal with OXB for access to advanced viral vector technologies, announced on March 18, 2026.
KOMO Biosciences Grants License to Syngenta for Maize Genome Tech
KOMO Biosciences has granted Syngenta a research license to evaluate its KOMbine platform for precision genome modification in maize, as announced on March 11, 2026.
